Systemic sclerosis & Raynaud's
Clinical and autoantibody associations with malignancy in systemic sclerosis: a systematic review and meta-analysis
Pooled result · Factors associated with malignancy in SScResult — go to the resultMD (age at SSc onset) +4.01 95% CI 1.24–6.78Authors' conclusion
Malignancy association in SSc is influenced by clinical phenotype and autoantibody profile.
Study context
- Population
- Patients with SSc in case-control and cohort studies (Embase, MEDLINE, Cochrane Library, inception to 7 December 2024)
- Participants
- 27,624 patients35 studies
- Comparison
- SSc patients with malignancy vs without malignancy
- Outcome
- Factors associated with malignancy in SSc
Methodological detailsrandom-effects meta-analysis, Newcastle-Ottawa Scale quality assessment
- Random-effects meta-analysis
- Newcastle-Ottawa Scale quality assessment
Pooled result
As reported in the abstract
MD (age at SSc onset)
+4.01
95% CI 1.24–6.78
- Male gender, OR
- 1.36
- Smoking, OR
- 1.27
- Pulmonary hypertension (PH), OR
- 1.32
- Interstitial lung disease (ILD), OR
- 1.41
- dcSSc, OR
- 1.14
- Positive anti-RNAPIII, OR
- 1.79
- Positive ACA, OR
- 0.83
- Negative ANA, OR
- 1.39
Further pooled results
Sensitivity analysis of high-quality studies
- Male gender, smoking, PH and anti-RNAPIII remained significant
Lung malignancy (subgroup)
- Male gender, OR
- 2.72
- Smoking, OR
- 2.38
- Anti-topo I, OR
- 2.45
- ILD, OR
- 2.98
- ACA (inverse), OR
- 0.32
Breast malignancy (subgroup)
- Anti-RNAPIII, OR
- 2.17
Early/concurrent malignancy (subgroup)
- Anti-RNAPIII, OR
- 2.85
Later malignancy development (subgroup)
- Digital ulceration, OR
- 0.39
Original publication
Clinical and autoantibody associations with malignancy in systemic sclerosis: a systematic review and meta-analysis. Rheumatology (Oxford). Published 2 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →